Skip to NavigationSkip to content

News

0
Boehringer Ingelheim
German firm will target eight therapy areas over next two years but warns of challenges ahead  
0
Swiss firm will axe support staff at its New Jersey site and elsewhere in America  
0
Will now compete with Novo Nordisk’s blockbuster GLP-1 drug Victoza
0
EU looking to safeguard mHealth as a way of helping patients whilst cutting down on healthcare costs  

Features

Low image

Eric Low, chief executive of Myeloma UK, discusses the meaning of innovation and the need for its consideration across the board...